Advertisement

Pharmacy World and Science

, Volume 23, Issue 3, pp 120–121 | Cite as

Digestive hemorrhage caused by a Meckel's diverticulum in a metformin‐treated patient: is there any connection?

  • M.A. Burrull‐madero
  • A. Del‐villar‐ruiz
  • S. Grau‐cerrato
  • M. Andreu‐garcia
  • A. Goday‐arno
Article

Abstract

An obese patient, not diabetic, treated with metformin for some weeks, was referred to us with severe inferior digestive hemorrhage, diagnosed with Meckel's diverticulum. Metformin is described as a glucose‐lowering agent for treatment of type 2 diabetes mellitus and as antiobesity drug, though results achieved with this last indication are not conclusive. But metformin has fibrinolytic features by means of diminished plasminogen activator inhibitor 1 activity. Although no coagulation study was done and the Meckel's diverticulum is normally associated with bleeding, the particular intensity of the following hemorrhage may have been favored by metformin.

Diabetes Fibrinolytic Hemorrhage Meckel's diverticulum Metformin 

References

  1. 1.
    UK Prospective Diabetes Study. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-6.Google Scholar
  2. 2.
    Anderson J. Obesity. BMJ 1972;1:560-3.Google Scholar
  3. 3.
    Dunn CJ, Peters DH. Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 1995;49:721-49.Google Scholar
  4. 4.
    Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. Diabetes Care 1993;16:621-9.Google Scholar
  5. 5.
    Janssen M, Rillaerts E, De Leeuw I. Effects of metformin on haemorheology, lipid parameters and insulin resistance in insulin-dependent diabetic patients. Biomed Pharmacother 1991;45:363-7.Google Scholar
  6. 6.
    Vague P, Juhan-Vague I, Alessi MC, Badier C, Valadier J. Metformin decreases the high plasminogen activator inhibition capacity, plasma insulin and trigliceride levels in nondiabetic obese subjects. Thromb Haemost 1987;57:326-8.Google Scholar

Copyright information

© Kluwer Academic Publishers 2001

Authors and Affiliations

  • M.A. Burrull‐madero
    • 1
  • A. Del‐villar‐ruiz
    • 2
  • S. Grau‐cerrato
    • 2
  • M. Andreu‐garcia
    • 3
  • A. Goday‐arno
    • 4
  1. 1.Servicio de FarmaciaHospital Universitario del MarBarcelonaSpain
  2. 2.Servicio de FarmaciaSpain
  3. 3.Servicio de Enfermedades DigestivasSpain
  4. 4.Servicio de EndocrinologiaSpain

Personalised recommendations